A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors

NCT05381909 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

157

Enrollment

INDUSTRY

Sponsor class

Stopped The research was terminated voluntarily due to changes in the company's business strategy regarding the development of BGB-24714, rather than any safety issues.

Conditions

Solid Tumor, Adult

Interventions

DRUG: BGB-24714
DRUG: Paclitaxel
DRUG: Carboplatin
DRUG: Docetaxel

Sponsor

BeiGene